Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Liminatus Pharma Inc Cl A (LIMN)

Liminatus Pharma Inc Cl A (LIMN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,859
  • Shares Outstanding, K 31,065
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,984 K
  • EBIT $ -2 M
  • EBITDA $ -2 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.12
  • Most Recent Earnings $-0.07 on 11/13/25
  • Next Earnings Date 03/05/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2100 +15.86%
on 02/20/26
2.8300 -91.40%
on 02/09/26
-0.3278 (-57.40%)
since 02/02/26
3-Month
0.2100 +15.86%
on 02/20/26
2.8300 -91.40%
on 02/09/26
-0.6693 (-73.34%)
since 12/02/25

Most Recent Stories

More News
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering

CERRITOS, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN)  (“Liminatus” or the “Company”) , a pre-clinical stage immuno-oncology company developing next-generation...

LIMN : 0.2465 (-2.57%)
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation

LA PALMA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today...

LIMN : 0.2465 (-2.57%)
Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative

LA PALMA, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies,...

LIMN : 0.2465 (-2.57%)
Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies

LA PALMA, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies,...

LIMN : 0.2465 (-2.57%)
Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy

LA PALMA, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies,...

LIMN : 0.2465 (-2.57%)
Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy

LA PALMA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies,...

LIMN : 0.2465 (-2.57%)

Business Summary

Liminatus Pharma LLC operates as a clinical-stage immuno-oncology company which develops novel cancer therapies. Liminatus Pharma LLC is based in LA Palma, California.

See More

Key Turning Points

3rd Resistance Point 0.3154
2nd Resistance Point 0.2951
1st Resistance Point 0.2740
Last Price 0.2465
1st Support Level 0.2326
2nd Support Level 0.2123
3rd Support Level 0.1912

See More

52-Week High 33.6600
Fibonacci 61.8% 20.8821
Fibonacci 50% 16.9350
Fibonacci 38.2% 12.9879
Last Price 0.2465
52-Week Low 0.2100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar